- Conditions
- Type 2 Diabetes, Depression, Insulin Resistance, Obesity, Adolescent Development
- Interventions
- Mindfulness-Based Intervention, Cognitive-Behavioral Therapy, Health Education
- Behavioral
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anemia
- Interventions
- INTERCEPT, Control
- Device
- Lead sponsor
- Cerus Corporation
- Industry
- Eligibility
- 11 Years and older
- Enrollment
- 581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 15 more
- Conditions
- HIV Infections
- Interventions
- Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 1,864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 51
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 397
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
- Conditions
- Surgical Site Infections
- Interventions
- DFA-02 Antibiotic Gel, DFA-02 Placebo Gel
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited, India
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 31
- States / cities
- Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 28 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 44
- States / cities
- Mobile, Alabama • Concord, California • Escondido, California + 40 more
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 1,613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 522
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
- Procedure · Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
- Conditions
- Achondroplasia
- Interventions
- TransCon CNP
- Drug
- Lead sponsor
- Ascendis Pharma Growth Disorders A/S
- Industry
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2039
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Wilmington, Delaware + 5 more
- Conditions
- Invasive Fungal Infection
- Interventions
- Isavuconazonium sulfate, Voriconazole, Posaconazole
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,015 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
- Conditions
- Chronic Hepatitis C
- Interventions
- PSI-7977, Daclatasvir, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 17
- States / cities
- Coronado, California • San Diego, California • Aurora, Colorado + 13 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Zenagamtide, Semaglutide, Placebo zenagamtide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,060 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 41
- States / cities
- La Jolla, California • Lancaster, California • Lincoln, California + 34 more
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Risdiplam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 3 Months to 24 Months
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Madera, California • Palo Alto, California + 5 more
- Conditions
- Hearing Loss, Children With Hearing Differences, Amplification, Speech Perception
- Interventions
- Hearing Aids
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Small Cell Lung Cancer
- Interventions
- Rovalpituzumab Tesirine, Cisplatin, Etoposide
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 21 more
- Conditions
- Leukemia, Myeloid
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more
- Conditions
- Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
- Interventions
- PF-08634404, Bevacizumab, Chemotherapy
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 254
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more
- Conditions
- Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency, Citrullinemia 1, ARGI Deficiency, ASL Deficiency, Argininosuccinic Aciduria, ASS Deficiency, Hyperargininemia
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Philadelphia, Pennsylvania + 2 more
- Conditions
- Advanced Cancer
- Interventions
- Assessing and Listening to Individual Goals and Needs (ALIGN)
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 98 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Smoking Cessation
- Interventions
- Varenicline 1mg BID, Varenicline 0.5mg BID, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 56
- States / cities
- Ozark, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 46 more
- Conditions
- Lung Cancer
- Interventions
- Bronchoscopies, Sputum Sample, Venipuncture
- Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes, Diabetes, Autoimmune, Diabetes type1, Autoimmune Diabetes, Diabetes Mellitus, Brittle, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Insulin-Dependent, 1, Diabetes Mellitus, Juvenile-Onset, Diabetes Mellitus, Ketosis-Prone, Diabetes Mellitus, Sudden-Onset, Insulin-Dependent Diabetes Mellitus 1, Juvenile-Onset Diabetes, Type 1 Diabetes Mellitus
- Interventions
- Bionic Pancreas, Usual Care
- Device · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Boston, Massachusetts
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 104
- States / cities
- Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more